Skip to main navigation Skip to search Skip to main content

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously.

Wolfgang Kamin*, Matthias Volkmar Kopp, Frank Erdnuess, Uwe Schauer, Stefan Zielen, Ulrich Wahn

*Corresponding author for this work
78   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously.'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology